Search research articles
Contact Us
Filters
Showing results (151-160 of 155) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 155 results.
BMC Infectious Diseases
|
January 20, 2021
Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study
Jesna Jose, Hasan M Al-Dorzi, Awad Al-Omari, et al.
The Lancet. Global Health
|
August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
Vijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
Vijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Cancer
|
June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer
Vijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 155) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 155 results.
BMC Infectious Diseases
|
January 20, 2021
Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study
Jesna Jose, Hasan M Al-Dorzi, Awad Al-Omari, et al.
The Lancet. Global Health
|
August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
Vijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
Vijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Cancer
|
June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer
Vijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Page
of 16